tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Bouchey, 5 are a BUY (100%).
Analyst David Bouchey, currently employed at AEGIS, carries an average stock price target met ratio of 33.33% that have a potential upside of 49.81% achieved within 417 days. Previously, David Bouchey worked at IFS.
David Bouchey’s has documented 10 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IINN, Inspira Technologies Oxy BHN Ltd at 24-Jan-2023.
Analyst best performing recommendations are on CBAY (CYMABAY THERAPEU).
The best stock recommendation documented was for CBAY (CYMABAY THERAPEU) at 8/11/2017. The price target of $13 was fulfilled within 186 days with a profit of $6.43 (97.87%) receiving and performance score of 5.26.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 13-May-2019
$20
$12.57 (169.18%)
$20
1 months 11 days ago
(11-Sep-2026)
0/23 (0%)
$12.04 (151.26%)
Buy Since 05-Oct-2023
$50
$42.57 (572.95%)
$50
1 years 7 months 1 days ago
(21-Mar-2025)
0/3 (0%)
$36.5 (270.37%)
Buy Since 24-Jun-2019
$50
$42.57 (572.95%)
$110
1 years 11 months 8 days ago
(14-Nov-2024)
1/2 (50%)
$25.1 (100.80%)
486
Buy Since 24-Jun-2019
6 years 7 months 25 days ago
(27-Feb-2020)
1/2 (50%)
$806.3 (275.56%)
491
Buy Since 14-Aug-2017
$1210
$1202.57 (16185.33%)
$1210
7 years 4 months 3 days ago
(19-Jun-2019)
0/2 (0%)
$866.8 (252.56%)
What Year was the first public recommendation made by David Bouchey?
